Koninklijke Philips N.V.
PHGNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $30.41 Prior regular-session close from the quote source.
- $29.81–$30.30 Regular-session low and high so far today.
- 1.8M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $23.62–$33.44 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own PHG if the company sustains recent margin improvement (driven by higher gross margins and cost actions), converts that operating recovery into repeatable free cash flow, and avoids new large product‑liability or regulatory charges that would wipe.
PHG price history
Loading recent earnings…
Investment thesis
What must happen next
Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges.StrengtheningMateriality: High
operating_income improved from -1529000000.0 EUR (FY2022) to -115000000.0 EUR (FY2023) to 529000000.0 EUR (FY2024) to 1424000000.0 EUR (FY2025). If true, Philips will convert flat revenue into rising operating profit and cash; if false, a reversal will quickly push earnings back into losses and erode valuation.
Watch: Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_income improved from -1529000000.0 EUR (FY2022) to -115000000.0 EUR (FY2023) to 529000000.0 EUR (FY2024) to 1424000000.0 EUR (FY2025).
Open source ↗Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside.HoldingMateriality: High
revenue has been roughly stable: 17156000000.0 EUR (FY2021), 17827000000.0 EUR (FY2022), 18169000000.0 EUR (FY2023), 18021000000.0 EUR (FY2024), 17834000000.0 EUR (FY2025). Margins can improve valuation, but sustained shareholder returns typically require both margin durability and top‑line growth; without revenue acceleration upside is limited to de‑risking and multiple re‑rating.
Watch: Secular volume declines in core markets or hospitals delaying capital spending.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue has been roughly stable: 17156000000.0 EUR (FY2021), 17827000000.0 EUR (FY2022), 18169000000.0 EUR (FY2023), 18021000000.0 EUR (FY2024), 17834000000.0 EUR (FY2025).
Open source ↗The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress.StrengtheningMateriality: Medium
cash and cash equivalents rose from 1172000000.0 EUR (FY2022) to 1869000000.0 EUR (FY2023) to 2401000000.0 EUR (FY2024) to 2794000000.0 EUR (FY2025). Adequate cash reduces existential risk from settlements/charges and gives management flexibility for investment or returns; loss of that buffer would materially increase downside.
Watch: A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash and cash equivalents rose from 1172000000.0 EUR (FY2022) to 1869000000.0 EUR (FY2023) to 2401000000.0 EUR (FY2024) to 2794000000.0 EUR.
Open source ↗Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward.HoldingMateriality: Medium
net_income swung from -1605000000.0 EUR (FY2022) and -698000000.0 EUR (FY2024) to 897000000.0 EUR (FY2025). Net income is the clearest proof investors care about; a new large charge would reverse the FY2025 recovery and damage credibility and valuation.
Watch: Regulators or courts require multi‑hundred‑million to billion‑euro remediation or settlement costs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
net_income swung from -1605000000.0 EUR (FY2022) and -698000000.0 EUR (FY2024) to 897000000.0 EUR (FY2025).
Open source ↗The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value.HoldingMateriality: Medium
equity decreased from 13283000000.0 EUR (FY2022) to 12061000000.0 EUR (FY2023) to 12043000000.0 EUR (FY2024) to 10990000000.0 EUR (FY2025). If equity decline is due to write‑downs or large returns of capital before contingencies are settled, owners bear outsized risk; prudent allocation preserves optionality.
Watch: Management announces large share repurchases or special dividends while major contingency reserves remain unresolved.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
equity decreased from 13283000000.0 EUR (FY2022) to 12061000000.0 EUR (FY2023) to 12043000000.0 EUR (FY2024) to 10990000000.0 EUR (FY2025).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges. If true, Philips will convert flat revenue into rising operating profit and cash; if false, a reversal will quickly push earnings back into losses and erode valuation.
Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside. Margins can improve valuation, but sustained shareholder returns typically require both margin durability and top‑line growth; without revenue acceleration upside is limited to de‑risking and multiple re‑rating.
The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress. Adequate cash reduces existential risk from settlements/charges and gives management flexibility for investment or returns; loss of that buffer would materially increase downside.
Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward. Net income is the clearest proof investors care about; a new large charge would reverse the FY2025 recovery and damage credibility and valuation.
The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value. If equity decline is due to write‑downs or large returns of capital before contingencies are settled, owners bear outsized risk; prudent allocation preserves optionality.
All standing thesis claims
Original report summary
the company sustains recent margin improvement (driven by higher gross margins and cost actions), converts that operating recovery into repeatable free cash flow, and avoids new large product‑liability or regulatory charges that would wipe.
Bull case and bear case
Bull case and bear case for Koninklijke Philips Nv
Where the evidence on Koninklijke Philips Nv stands: Holding on the latest evidence (Nov 6, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.
Bull case: what the evidence supports
Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges.
Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside.
The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress.
Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward.
The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value.
Bear case: what would count against it
Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.
Secular volume declines in core markets or hospitals delaying capital spending.
A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.
Thesis-Break Engine
Thesis-break watch · Koninklijke Philips Nv
No break has crossed Koninklijke Philips Nv’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
Koninklijke Philips Nv filed an SEC report on 2026-11-03: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Koninklijke Philips Nv filed an SEC report on 2026-07-28: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Koninklijke Philips Nv filed an SEC report on 2026-06-02: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.
- Secular volume declines in core markets or hospitals delaying capital spending.
- A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.
- Regulators or courts require multi‑hundred‑million to billion‑euro remediation or settlement costs.
- Management announces large share repurchases or special dividends while major contingency reserves remain unresolved.
PHG news
Loading headlines…
Financial statements
PHG income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
PHG: quick answers
- What is PHG's short interest?
- As of October 30, 2026, 2.1M PHG shares were sold short, down 25.6% from the count before. At the stock's average daily volume that is 1.7 days to cover. FINRA publishes the count twice a month. PHG short interest history
- Have members of Congress traded PHG?
- 26 trades in PHG have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed PHG trade
